Status:
RECRUITING
Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease
Lead Sponsor:
Boston Children's Hospital
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
12-25 years
Phase:
NA
Brief Summary
Adolescents and young adults with sickle cell disease (SCD) face challenges managing their illness and maintaining their well-being. This study proposes to test the feasibility and acceptability of a ...
Detailed Description
Adolescents and Young Adults (AYAs) with blood disorders are at risk for poor physical, psychological, and social outcomes. Sickle Cell Disease (SCD) is a life-limiting condition, defined as a group o...
Eligibility Criteria
Inclusion
- Aged ≥ 12 and ≤ 25 years of age at baseline
- Diagnosed with Sickle Cell Disease (HbSS, HbSC, HbS-Beta Thalassemia, and other related hemoglobinopathies)
- Receiving Medical Care at the DFCI/BCH Blood Disorders Center.
- Scored \> 9 on Patient Health Questionnaire 9-item (PHQ-9) or Generalized Anxiety Disorder (GAD)
- Able to speak English or Spanish language (for PRISM sessions)
- Able to read English or Spanish language (for completion of surveys)
- Cognitively able to participate in PRISM sessions and complete written questionnaires and surveys, as judged by the site investigator
- Willing and able to adhere to the study visit schedule and other protocol requirements
Exclusion
- \* does not meet above criteria
Key Trial Info
Start Date :
October 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2030
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06555939
Start Date
October 23 2025
End Date
September 1 2030
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston Children's Hospital
Boston, Massachusetts, United States, 02115